Loading...
Please wait, while we are loading the content...
Similar Documents
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
| Content Provider | Semantic Scholar |
|---|---|
| Author | Chue, Pierre S. |
| Copyright Year | 2007 |
| Abstract | OBJECTIVE To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone. METHODS Studies published between January 2000 and October 2006 evaluating the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were reviewed, as identified from literature searches using Medline and EMBASE. Abstracts and posters on long-acting risperidone presented at key psychiatry congresses and available in the public domain during this time period were also reviewed. RESULTS The unique pharmacokinetic profile of long-acting risperidone is derived from the encapsulation of risperidone in a glycolide/lactide matrix in the form of microspheres such that after a single intramuscular injection, significant plasma levels of the drug are achieved after week 3. Steady state, after repeated administration at 2-week intervals, is achieved after 3 injection cycles. Short- and long-term studies have demonstrated that long-acting risperidone (25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with schizophrenia and related psychoses. Most patients can be switched from other oral and long-acting antipsychotic agents without compromising efficacy and safety. Long-acting risperidone may also reduce overall healthcare costs by decreasing rates of relapse and hospitalization. CONCLUSION The assured delivery of an atypical antipsychotic medication with long-acting risperidone has important implications for patient compliance, maintenance of stability, consistency of treatment, and improving patient outcomes including the achievement of remission. |
| Starting Page | 13 |
| Ending Page | 39 |
| Page Count | 27 |
| File Format | PDF HTM / HTML |
| DOI | 10.2147/nedt.2007.3.1.13 |
| PubMed reference number | 19300536 |
| Journal | Medline |
| Volume Number | 3 |
| Alternate Webpage(s) | http://www.romjpsychiat.ro/uploads/files/412240584bc8d5d5d2b68b7135c1b5f4.pdf |
| Alternate Webpage(s) | http://ftp.ncbi.nlm.nih.gov/pub/pmc/29/1c/NDT-3-13.PMC2654523.pdf |
| Alternate Webpage(s) | https://doi.org/10.2147/nedt.2007.3.1.13 |
| Journal | Neuropsychiatric disease and treatment |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
